Bioton H1 Loss on Court Reserve; Domestic Insulin Market Shrinks 11%

Bioton reported a significant H1 loss, attributed to a reserve related to a court ruling, while the domestic human insulin market contracted 11% year-on-year. The company is seeking alternative revenue sources amid the market decline. The loss is non-operational, but the market shrinkage signals structural pressure on core business.